CLINICAL TRIALS PROFILE FOR LOPURIN

All Clinical Trials for LOPURIN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00899431 ↗	Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)	Terminated	Celgene Corporation	Phase 2	2009-05-06	The goal of this clinical research study is to learn if lenalidomide, when given with a stem cell transplant and chemotherapy (bendamustine, fludarabine, and rituximab), can help to control CLL. The safety of this treatment combination will also be studied.
NCT00899431 ↗	Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)	Terminated	M.D. Anderson Cancer Center	Phase 2	2009-05-06	The goal of this clinical research study is to learn if lenalidomide, when given with a stem cell transplant and chemotherapy (bendamustine, fludarabine, and rituximab), can help to control CLL. The safety of this treatment combination will also be studied.
NCT01685411 ↗	Busulfan and Cyclophosphamide Followed By ALLO BMT	Terminated	Masonic Cancer Center, University of Minnesota	N/A	2013-01-01	This is a treatment guideline to allow routine clinical data to be collected and maintained in Oncore (clinical database) and the University of Minnesota Blood and Marrow Database as part of the historical database maintained by the department.

Clinical Trial Conditions for LOPURIN

Condition Name

Condition Name for LOPURIN
Intervention	Trials
Chronic Lymphocytic Leukemia	2
Acute Lymphoblastic Leukemia	1
Acute Myeloid Leukemia	1

Condition MeSH

Condition MeSH for LOPURIN
Intervention	Trials
Leukemia, Lymphoid	3
Leukemia	3
Leukemia, Lymphocytic, Chronic, B-Cell	2

Clinical Trial Locations for LOPURIN

Trials by Country

Trials by Country for LOPURIN
Location	Trials
United States	3

Trials by US State

Trials by US State for LOPURIN
Location	Trials
Texas	2
Minnesota	1

Clinical Trial Progress for LOPURIN

Clinical Trial Phase

Clinical Trial Phase for LOPURIN
Clinical Trial Phase	Trials
Phase 2	2
N/A	1

Clinical Trial Status

Clinical Trial Status for LOPURIN
Clinical Trial Phase	Trials
Terminated	2
Recruiting	1

Clinical Trial Sponsors for LOPURIN

Sponsor Name

Sponsor Name for LOPURIN
Sponsor	Trials
M.D. Anderson Cancer Center	2
Celgene Corporation	1
Masonic Cancer Center, University of Minnesota	1

Sponsor Type

Sponsor Type for LOPURIN
Sponsor	Trials
Other	3
Industry	2
NIH	1

LOPURIN: Clinical Trials Update, Market Analysis, and 2026 to 2035 Projection

Last updated: April 24, 2026

What is LOPURIN and what is the current evidence base?

No credible public record of a drug product named LOPURIN with identifiable active ingredient(s), sponsor(s), trial identifiers (NCT/EudraCT/CTIS), mechanism of action, or regulatory status is available in the information provided. Without an unambiguous identity for “LOPURIN,” clinical-trial mapping, market sizing, and forecast modeling cannot be produced.

What clinical trials are active, ongoing, or completed for LOPURIN?

A complete clinical trials update requires at minimum: (1) the drug’s generic name (or development code), (2) trial registry IDs, and (3) indication(s). None are provided for “LOPURIN,” so no factual trial timeline can be stated.

How large is the market for LOPURIN by indication, geography, and segment?

Market analysis requires the target indication, patient population, and comparator set. Because “LOPURIN” is not uniquely identified to an active ingredient and indication set, there is no defensible way to calculate addressable market, share assumptions, pricing, or channel mix.

What does the forecast look like for revenue and uptake from 2026 to 2035?

A forecast depends on: regulatory milestones, label scope, penetration curve, price and reimbursement, adherence dynamics, and competitive timelines. Since “LOPURIN” is not uniquely identified, a revenue or units projection would be fabricated.

---

Key Takeaways

• “LOPURIN” is not uniquely identifiable from the information provided (no active ingredient, indication, trial IDs, or regulatory status).
• A clinical trials update cannot be produced without trial registries tied to a specific drug identity.
• Market sizing and 2026 to 2035 projection cannot be produced without an indication, comparator set, and pricing basis.

FAQs

1. Is LOPURIN a registered brand for a specific generic drug?
   Not determinable from the provided information.

2. Are there clinical trial registry entries for LOPURIN?
   Not determinable without the active ingredient or trial identifiers.

3. What indications is LOPURIN in development or approved for?
   Not determinable from the provided information.

4. Can revenue forecasts be generated without indication and label scope?
   No. Forecast assumptions require indication, competitive context, and pricing.

5. What data inputs are required to produce a defensible forecast?
   Active ingredient identity, indication(s), trial IDs, regulatory status, and an evidence-based pricing and reimbursement baseline.

---

References

[1] No cited sources available based on the provided information.